Serial volumetric assessment of coronary fibroatheroma by optical frequency domain imaging: insights from the TROFI trial — Carlos M. Campos (2017) | RDL Network
Serial volumetric assessment of coronary fibroatheroma by optical frequency domain imaging: insights from the TROFI trial
European Heart Journal - Cardiovascular Imaging 19(1): 92-100
Article 2017 English
Authors
CC
Carlos M. Campos
HG
Héctor M. García‐García
JI
Javaid Iqbal
Abstract
1 min read
Coronary lesions precursors of acute events remain elusive, since they undergo continuous changes and their temporal changes are not very well-characterized. In natural history studies, optical frequency domain imaging (OFDI) has been used only to assess fibroatheromas as a 2D structure and sometimes in a single frame fashion. We aim at describing the serial volumetric modifications of the fibrous cap (FC) of the fibroatheromas as determined by OFDI over a 6-month follow-up period.In 49 patients, OFDI investigation was performed following treatment of culprit lesion and at 6-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI). A fully automatic volumetric quantification of FC was done in all lipid-containing frames of non-culprit lesions in the infarct related artery. These lesions were matched at baseline and 6-month follow-up. A total of 58 non-culprit lipid rich lesions (34 TCFAs and 24 thick-cap fibroatheroma [ThCFA]) were found in 34 patients at baseline. Overall, there was a FC volume decrease of 1.57 (Inter-quartile Range [IQR] -4.13 to 0.54) mm3 at 6-months. 27% of the lesions changed their phenotype over time (TCFA or ThCFA). TCFAs that became ThCFAs at follow-up had smaller mean and maximal FC as compared with lesions that remained TCFAs (P = 0.01 for both).Non-culprit fibroatheromas located in the infarct related artery of patients with STEMI had a volumetric reduction of the FC after 6-month follow-up. Quantitative FC assessment was able to differentiate high-risk lesions that became ThCFAs. There was a considerable change of plaque phenotype (TCFAs or ThCFAs) over time.
Héctor M. García‐García, Takashi Muramatsu, Shimpei Nakatani, I.-S. Lee, Niels Ramsing Holm, Leif Thuesen, Robert‐Jan van Geuns, Martin van der Ent, Vladimir Borovicanin, Dragica Paunovic, Y. Onuma, Patrick W. Serruys
Takashi Muramatsu, Héctor M. García‐García, Yoshinobu Onuma, Yao‐Jun Zhang, Christos V. Bourantas, Roberto Diletti, Javaid Iqbal, Maria Radu, Yukio Ozaki, Patrick W. Serruys, on behalf of the TROFI investigators
Peter H. Stone, Akiko Maehara, Ahmet U. Coskun, Charles Maynard, Marina Zaromytidou, Gerasimos Siasos, Ioannis Andreou, Dimitrios I. Fotiadis, Kostas Stefanou, Michail I. Papafaklis, Lampros K. Michalis, Alexandra J. Lansky, Gary S. Mintz, Patrick W. Serruys, Charles L. Feldman, Gregg W. Stone
Lorenz Räber, Konstantinos C. Koskinas, Kyohei Yamaji, Masanori Taniwaki, Marco Roffi, Lene Holmvang, Hector M. Garcia Garcia, Thomas Zanchin, Rafaela Maldonado, Aris Moschovitis, Giovanni Pedrazzini, Serge Zaugg, Jouke Dijkstra, Christian M. Matter, Patrick W. Serruys, Thomas F. Lüscher, Henning Kelbæk, Alexios Karagiannis, Maria Radu, Stephan Windecker
Discussion(0)
No comments yet. Be the first to comment.